Table 1:

Baseline characteristics and outcomes of randomized patientsa

Characteristic<150-mm Hg Target (n = 37)<180-mm Hg Target (n = 36)P Value
Age (yr)71.0 ± 12.568.7 ± 11.1.40
Male26 (70%)28 (78%).47
Symptom onset to randomization (hr)10.5 ± 7.49.7 ± 7.0.65
Medical history
    Hypertension26 (70%)27 (75%).71
    Previous ICH4 (11%)1 (3%).19
    Antiplatelet/anticoagulation4 (11%)4 (11%).74
    Ischemic stroke6 (16%)2 (6%).17
Clinical characteristics
    Systolic BP (mm Hg)182 ± 20184 ± 25.66
    Diastolic BP (mm Hg)94 ± 1997 ± 23.53
    Mean arterial pressure (mm Hg)123 ± 17126 ± 22.54
    Glasgow Coma Scale13.3 ± 2.713.9 ± 1.9.27
    NIHSS score12.3 ± 7.711.5 ± 6.3.64
Hematoma characteristics
    Basal ganglia28 (76%)27 (75%).99
    Lobar9 (24%)8 (22%)
    Cerebellum0 (0%)1 (3%)
    Intraparenchymal volume (mL)24.5 ± 28.922.61 ± 21.35.75
    Intraventricular volume (mL)2.20 ± 6.264.25 ± 8.78.26
    Total ICH volume (mL)26.68 ± 31.5026.86 ± 25.24.98
Antihypertensive therapyb
    Labetalol (No.) (mean dose ± SD in mg)34 (38 ± 25)16 (29 ± 25)
    Hydralazine (No.) (mean dose ± SD in mg)18 (22 ± 14)5 (14 ± 8)
    IV enalapril (No.) (mean dose ± SD in mg)9 (1.25 ± 0)3 (1.25 ± 0)
Outcomes
    Mortality (No.) (%)7 (19)4 (11).52
    Modified Rankin Scale score (median) (IQR)3 (1.5–5.5)4 (2–5).43
    Hematoma growth >6 mL (No.) (%)8 (21)8 (22).86
  • Note:—IQR indicates interquartile range.

  • a Data are means unless otherwise specified.

  • b Nineteen patients in the <150-mm Hg group and 2 patients in the <180-mm Hg group received multiple antihypertensives.